Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
protein_peptide
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05093335CT.gov In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Erdheim-Chester Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Boclatixafortide (this asset) | Memorial Sloan Kettering Cancer Center | Early P1 | C · 39 |
| Dabrafenib | Cancer Research UK | P2/3 | B |
| Cobimetinib | Cancer Research UK | P2/3 | B |
| Trametinib | Cancer Research UK | P2/3 | B |
| Vemurafenib | Cancer Research UK | P2/3 | CCC |
| hlx208 | Shanghai Henlius Biotech | P2 | CCC |
| hh2710 | Haihe Biopharma Co., Ltd. | P1/2 | CCC |
| Cetuximab | M.D. Anderson Cancer Center | P1 | CC |
| q702 | Mayo Clinic | P1 | CC |
+2 more in the Erdheim-Chester Disease cohort
Other indications for Boclatixafortide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Marginal Zone Lymphoma | — | P3 | CCC · 54 |
| Indolent B-Cell Non-Hodgkin Lymphoma | — | P2 | CCC · 53 |
| Primary Central Nervous System Lymphoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Boclatixafortide in Erdheim-Chester Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/14710-tetraazacyclododecane-147-triacetic-acid-10-2-4-3-2r5s8s14r-5-3-aminoiminomethylaminopropyl-14-4-hydroxyphenylmethyl-1-methyl-8-2-naphthalenylmethyl-3691215-pentaoxo-1471013-pentaazacyclopentadec-2-ylpropylaminocarbonylphenylmethylamino-2-oxoethyl-erdheim-chester-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →